glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) 비교

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	ADCStandard DatabasestalePhase 2 nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)) Celldex Therapeutics·PD-1 60 trials

Overview Program	glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
Overview Company	Celldex Therapeutics
Overview Modality	ADC
Overview Target	PD-1
Overview Indication	Melanoma
Overview Phase	PHASE_2
Overview Status	DISCONTINUED
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway
MoA Biomarker	PD-1 blockade and high

PK/PD Species	Mouse
PK/PD Animal (cat.)	Mouse
PK/PD Experiment	pharmacokinetic

Toxicology Species	Mouse
Toxicology Animal (cat.)	Mouse
Toxicology Major finding	pneumonitis, metabolic dysregulation, and recurrent sepsis requiring intensive care

Clinical Safety signal	pneumonitis, metabolic dysregulation, and recurrent sepsis requiring intensive care
Clinical Selected reported efficacy	ORR 50%
Clinical Reported ORR	50%
Clinical Result source	ClinicalTrials.gov NCT03150329
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT03150329

선택됨 (1/5)

추천 · 인기 프로그램

최대 5개 선택 · 전체 25+ 프로그램은 검색으로 찾을 수 있습니다. ADC 목록 →

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	ADCStandard DatabasestalePhase 2 nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)) Celldex Therapeutics·PD-1 60 trials

Overview Program	glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
Overview Company	Celldex Therapeutics
Overview Modality	ADC
Overview Target	PD-1
Overview Indication	Melanoma
Overview Phase	PHASE_2
Overview Status	DISCONTINUED
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway
MoA Biomarker	PD-1 blockade and high

PK/PD Species	Mouse
PK/PD Animal (cat.)	Mouse
PK/PD Experiment	pharmacokinetic

Toxicology Species	Mouse
Toxicology Animal (cat.)	Mouse
Toxicology Major finding	pneumonitis, metabolic dysregulation, and recurrent sepsis requiring intensive care

Clinical Safety signal	pneumonitis, metabolic dysregulation, and recurrent sepsis requiring intensive care
Clinical Selected reported efficacy	ORR 50%
Clinical Reported ORR	50%
Clinical Result source	ClinicalTrials.gov NCT03150329
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT03150329